BA
CASC

BlackRock Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

BlackRock Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$111K Sell
25,806
-2,162
-8% -$14K ﹤0.01% 3000
2016
Q3 		$275K Sell
27,968
-6,619
-19% -$46.9K ﹤0.01% 2511
2016
Q2 		$196K Sell
34,587
-5,693
-14% -$38.7K ﹤0.01% 2618
2016
Q1 		$307K Hold
40,280
– – ﹤0.01% 2329
2015
Q4 		$537K Sell
40,280
-4,883
-11% -$84.1K ﹤0.01% 2045
2015
Q3 		$742K Sell
45,163
-4,016
-8% -$82.3K ﹤0.01% 1910
2015
Q2 		$1.1M Buy
49,179
+6,223
+14% +$98.4K ﹤0.01% 1589
2015
Q1 		$420K Buy
42,956
+34,695
+420% +$340K ﹤0.01% 2208
2014
Q4 		$94K Hold
8,261
– – ﹤0.01% 3080
2014
Q3 		$95K Buy
8,261
+311
+4% +$4.75K ﹤0.01% 3035
2014
Q2 		$155K Buy
7,950
+5,355
+206% +$94.5K ﹤0.01% 2797
2014
Q1 		$47K Hold
2,595
– – ﹤0.01% 3271
2013
Q4 		$27K Buy
2,595
+797
+44% +$8.91K ﹤0.01% 3341
2013
Q3 		$22K Hold
1,798
– – ﹤0.01% 3305
2013
Q2 		$17K Buy
+1,798
New +$23.1K ﹤0.01% 3305

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock Advisors's CASC Position: Q4 2016 in Review

BlackRock Advisors reduced its Cascadian Therapeutics, Inc. (CASC) stake by 7.7% in Q4 2016, selling an estimated $14K and leaving 25,806 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #3000.

BlackRock Advisors first reported a position in CASC in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.1M in Q2 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • BlackRock Advisors held 25,806 shares of Cascadian Therapeutics, Inc. worth $111K as of Q4 2016.
  • BlackRock Advisors sold 2,162 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $14K.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3000 holding.
  • BlackRock Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Cascadian Therapeutics, Inc. position peaked at $1.1M in Q2 2015.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.